Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. (scientific article published on 19 August 2014)

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Q58448492

Inhibition of human gastric lipase secretion by glucagon-like peptide-1

Q58448964

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

Q58449089

Diagnosis and Classification of Diabetes Mellitus

Q22255454

Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions

Q28252652

Sitagliptin, a DPP-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans

Q33789371

Intestinal metabolism of plasma free fatty acids. Intracellular compartmentation and mechanisms of control

Q34476816

Apoprotein composition of very low density lipoproteins of human serum

Q35902081

Fatty acids and insulin resistance in muscle and liver

Q36324076

Incretins and the development of type 2 diabetes

Q36560963

Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs

Q37004575

The incretin system and its role in type 2 diabetes mellitus

Q37266863

Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol

Q37333546

Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans

Q37418446

Key intestinal genes involved in lipoprotein metabolism are downregulated in dyslipidemic men with insulin resistance.

Q37590276

Hepatic triacylglycerol synthesis and secretion: DGAT2 as the link between glycaemia and triglyceridaemia

Q38089264

Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans

Q40341458

Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man.

Q40371487

Intestinal lipoprotein production is stimulated by an acute elevation of plasma free fatty acids in the fasting state: studies in insulin-resistant and insulin-sensitized Syrian golden hamsters

Q42465181

Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related ki

Q42494078

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

Q43014666

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Q43231241

Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study

Q44007374

Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia

Q46537808

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Q46919674

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes.

Q47268210

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

Q51381989

Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes.

Q51476370

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Q51495360

Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans.

Q51499984

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Q51599426

P433

issue

P921

main subject

lipoprotein

triglyceride

type 2 diabetes

page(s)

1223-1229

P577

publication date

2014-08-19

P1433

published in

Diabetes, Obesity and Metabolism

Q5270109

P1476

title

Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes

P478

volume

Reverse relations

cites work (P2860)

Q58702412	Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial
Q51276064	Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Q38663559	Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.
Q35890612	Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men.
Q89267034	Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance
Q91943169	Plasma biomarkers of small intestine adaptations in obesity-related metabolic alterations
Q42635500	Postprandial Dyslipidemia: Pathophysiology and Cardiovascular Disease Risk Assessment
Q48221983	Protective effects of dietary polyphenols from black soybean seed coats on islet and renal function in streptozotocin-induced diabetic rats.
Q49577642	Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial
Q50070044	The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus

P356	DOI	10.1111/DOM.12359
P8608	Fatcat ID	release_nlqjljar7zat5ccuz5lpyh56gu
P698	PubMed publication ID	25059982
P5875	ResearchGate publication ID	264245992